Validation of the electronic PASI application: establishing measurement equivalence

FM Ali\(^1\) (MBChB), MS Salek\(^{2,3}\) (PhD), AY Finlay\(^1\) (MBBS), V Piguet\(^{1,4}\) (MD),

\(^1\)Department of Dermatology and Academic Wound Healing, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK

\(^2\)School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK

\(^3\)Institute for Medicines Development, Cardiff, UK

\(^4\)Division of Dermatology, Department of Medicine, University of Toronto; Division of Dermatology, Women's College Hospital, Toronto, Canada

Running head: Validation of electronic PASI

*Correspondence:

- Dr Faraz Ali, Department of Dermatology, Division of Infection and Immunity, School of Medicine, Cardiff University, 3rd Floor Glamorgan House, Heath Park, Cardiff CF14 4XN, UK
  - email: AliFM@cardiff.ac.uk, tel: +44 29 2074 5874

**Funding:** The study was supported by a research grant from Janssen-Cilag Limited
Conflicts of Interest

FA has received travel expenses for attending AAD meetings from Janssen-Cilag Limited. FA has received lecture fees from Leo Pharmaceuticals.

AYF is joint copyright owner of the DLQI. Cardiff University and AYF receive royalties. AYF is a member of a Novartis Advisory Board and has received lecture fees and travel expenses from Novartis.

VP undertakes personal advisory work for Pfizer, AbbVie, Janssen, UCB, Novartis, Almirall and Celgene. He has received departmental support from AbbVie, Bausch Health, Celgene, Janssen, LEO Pharma, Lilly, NAOS, Novartis, Pfizer, Pierre-Fabre, and Sanofi.

Keywords: electronic, validation, equivalence, PASI, clinical outcome measures

Letter word count: 498
Manuscript table count: 1
Manuscript figure count: 1

ORCID Numbers:

Faraz Ali: 0000-0002-4184-2023
Sam Salek: 0000-0002-4612-5699
Andrew Finlay: 0000-0003-2143-1646
Vincent Piguet: 0000-0001-6079-4517
Despite its many shortcomings, the Psoriasis Area and Severity Index (PASI) remains the standard method worldwide for psoriasis assessment. Several studies have implemented electronic versions without evidence of formal validation, raising the possibility of lack of equivalence with the paper counterpart. This study aimed at comparing the conventional paper-based and a novel electronic application version of the PASI (Figure 1). International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines were followed to assess rater preference and consistency of scores.

The study employed a randomized cross-over design using a within-subjects comparison of the two formats of the PASI. The study was conducted at the dermatology outpatient department, University Hospital of Wales, Cardiff, UK. Inclusion criteria were: patients aged 18 years or older with a clinical diagnosis of chronic plaque psoriasis from a dermatologist and the ability to read and understand English. Raters ranged from medical students to senior trainees and received standardised clinical training for PASI assessment to ensure uniformity of rating. The study power was 80%, with an expected intra-class correlation coefficient (ICC) of 0.9 (α = 0.05), resulting in a target sample size of 44 patients.

All three raters showed high correlation in test scores (Pearson-correlation 0.949, p<0.05, n=5) demonstrating standardisation of the assessment criteria. Forty-four patients were recruited, mean age 45 years (SD ± 16, 59.1% male). The mean duration of chronic plaque psoriasis diagnosis was 19.2 years (SD ± 14.8, interquartile range, IQR, 8-30), with PASI severity ranging from 0.7 to 28.5. The ICC showed high concordance between the total PASI scores from paper and iPad.
The median difference in PASI scores was also within the hypothesized difference of $CC = 0.993 \ (p=0.72)$. The lower and higher limits of agreement were -1.4 and 1.4, respectively.

The PASI iPad® version demonstrated reduced inter-rater variability compared to the paper version (Pearson correlation 0.982 vs 0.949, number of patients assessed=5). There was no carryover effect demonstrated with scores ($p=0.82$) or time to completion ($p=0.16$) regardless of which format of the PASI was used first. The raters, using a stopwatch, took a median of 147 seconds (iPad®) versus 152 seconds (paper), not including calculation time ($p=0.81$). Raters reported that the iPad version was easier to use compared to the paper version due to the visual nature of the application allowing accurate assessment and calculation of severity scores, though suggestions were made to improve the user interface.

The future of medical practice is intricately anchored within the evolution of digital technology. There is high correlation, and thus equivalence, between the PASI iPad® and paper versions. The raters preferred the iPad version due to the visual nature of the scoring process and the reduced likelihood of calculation errors. The higher inter-rater reliability and the inherent advantages of electronic tools further re-enforces the superiority of the digital format. The validated Psoriasis 360 application®, together with the previously validated DLQI® component, has the potential to be of considerable value to clinicians, researchers and patients.
REFERENCES


Table 1 Equivalence analysis of paper and electronic PASI overall mean scores and mean completion time

<table>
<thead>
<tr>
<th></th>
<th>Paper</th>
<th>iPad®</th>
<th>ICC* (95% CI)</th>
<th>Difference (P - I)</th>
<th>Limits of agreement‡</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PASI scores</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=104)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>5.7 (2.1-10.7)</td>
<td>5.8 (2.7-9.3)</td>
<td>0.993 (0.988 - 0.996)</td>
<td>0.0 (-0.3 – 0.4)†</td>
<td>-1.4 1.4</td>
</tr>
<tr>
<td><strong>PASI times</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(mins:seconds)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>2:32 (01:55-03:07)</td>
<td>2:27 (01:54-03:00)</td>
<td>0.444 (0.148 - 0.665)</td>
<td>-00:10 (-00:31-00:40)†</td>
<td></td>
</tr>
</tbody>
</table>

CI = confidence interval, ICC = intraclass correlation, IQR = interquartile range, SD = standard deviation

* Hypothesizing coefficient of ≥ 0.9
† p value > 0.05 calculated by Wilcoxon Signed Rank test
‡ Limits of agreement calculated from Bland-Altman plots
**Figures**

**Figure 1** Example screenshot from the PASI iPad App

Step 3

Which image represents the severity of redness on the trunk?

- MILD
- MODERATE
- SEVERE
- VERY SEVERE
- NONE